{"id":"NCT03725033","sponsor":"Materia Medica Holding","briefTitle":"Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance","officialTitle":"Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-10","primaryCompletion":"2020-03-23","completion":"2020-03-23","firstPosted":"2018-10-30","resultsPosted":"2021-01-14","lastUpdate":"2021-02-04"},"enrollment":538,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Impaired Glucose Tolerance"],"interventions":[{"type":"DRUG","name":"Subetta","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Subetta","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Purpose of the study:\n\n* to assess the efficacy of Subetta in the treatment of impaired glucose tolerance\n* to assess the safety of Subetta in the treatment of impaired glucose tolerance.","primaryOutcome":{"measure":"Change 2-hour Plasma Glucose (During Oral Glucose Tolerance Test).","timeFrame":"At baseline and after 12 weeks of treatment.","effectByArm":[{"arm":"Subetta","deltaMin":9.27,"sd":0.88},{"arm":"Placebo","deltaMin":9.11,"sd":0.86}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0028"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":44,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Diabetes mellitus","Acute respiratory tract infection","Increase of blood pressure","Headache","Vomiting"]}}